Replies to post #14132 on The Rising Influence of Rising Affluence

[jbog]

I've always liked NVO and probably feel it could be priced right at these levels.

What's holding me back is that I feel there will be certain pharma sectors who'll have to correct their pricing models.

As an individual drug Humira would have to be number #1, and then closely followed the Diabetes, MS and Cancer groups.

The model is nothing besides silly.